Long-Term Outcomes of Carbon Dioxide Insufflation in Thoracoscopic Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study

Thoracoscopic esophagectomy (TE) with carbon dioxide (CO ) insufflation is increasingly performed for esophageal cancer; however, there is limited evidence of the long-term outcomes of CO insufflation on postoperative survival. We investigated the long-term outcomes of TE with or without CO insuffla...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Curēus (Palo Alto, CA) CA), 2024-07, Vol.16 (7), p.e65053
Hauptverfasser: Otsuka, Koji, Goto, Satoru, Ariyoshi, Tomotake, Yamashita, Takeshi, Saito, Akira, Kohmoto, Masahiro, Kato, Rei, Motegi, Kentaro, Yajima, Nobuyuki, Murakami, Masahiko
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Thoracoscopic esophagectomy (TE) with carbon dioxide (CO ) insufflation is increasingly performed for esophageal cancer; however, there is limited evidence of the long-term outcomes of CO insufflation on postoperative survival. We investigated the long-term outcomes of TE with or without CO insufflation. We enrolled 182 patients who underwent TE for esophageal cancer between January 2003 and October 2013 and categorized them into two groups: with and without CO insufflation. The primary endpoint was five-year overall survival (5y-OS). Secondary endpoints included long-term outcomes, such as five-year relapse-free survival (5y-RFS) and five-year cancer-specific survival (5y-CSS), and short-term outcomes, such as surgical and non-surgical complications and reoperation within 30 days. Follow-up until death or the five-year postoperative period was 98.9% (median follow-up duration was six years in survivors). After adjusting for age, sex, and yield pathologic tumor, node, and metastasis (TNM) stage, we found no significant differences in 5y-OS (HR 1.12, 95% CI 0.66-1.91), 5y-RFS (HR 1.12, 95% CI 0.67-1.83), or 5y-CSS rates (HR 1.00, 95% CI 0.57-1.75). For short-term outcomes, significant intergroup differences in operation time (p=0.02), blood loss (p
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.65053